KraneShares has expanded its European ETF range with the launch of a China healthcare strategy.
The KraneShares MSCI All China Health Care Index UCITS ETF (KURE) is listed on the London Stock Exchange (LSE) with a total expense ratio (TER) of 0.65%.
Tracking the MSCI China All Shares Health Care 10/40 index, KURE offers exposure to Chinese companies involved in the healthcare industry.
This includes businesses in areas such as patent and generic pharmaceuticals, hospital administration, biotechnology, medical equipment production, healthcare IT and traditional Chinese medicine.
Jonathan Krane, CEO of KraneShares, commented: “We believe China’s healthcare sector presents a compelling investment growth opportunity.
“We see several long-term catalysts for the sector, including increasing demand for health care from China’s ageing population, a rising middle class, increasing health care spending per capita, innovation, and technological advancement.”
The firm already runs a mirror strategy in the US under the same ticker, KURE, which has gathered $180m assets under management (AUM) since launch in January 2018. The US-listed KURE has returned 70.4% over the past year, as at 14 January.
The China ETF specialist launched two strategies last year. The $26m KraneShares MSCI China ESG Leaders UCITS ETF (KESG), which offers exposure to Chinese companies with strong ESG scores, was brought to market in February 2020.
Subsequently last May, the firm launched its first fixed income ETF in Europe, the $8m KraneShares Bloomberg Barclays China Bond Inclusion UCITS ETF (KBND).
